CoChat

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors

Open access

The DOI matches its Crossref record; 150 of the 152 references it cites were found in a registry or an index.

Abstract

Immunotherapy has revolutionized the established therapeutics against tumors. As the major immunotherapy approach, immune checkpoint inhibitors (ICIs) achieved remarkable success in the treatment of malignancies. However, the clinical gains are far from universal and durable, because of the primary and secondary resistance of tumors to the therapy, or side effects induced by ICIs. There is an urgent need to find safe combinatorial strategies that enhance the response of ICIs for tumor treatment. Diets have an excellent safety profile and have been shown to play pleiotropic roles in tumor prevention, growth, invasion, and metastasis. Accumulating evidence suggests that dietary regimens bolster not only the tolerability but also the efficacy of tumor immunotherapy. In this review, we discussed the mechanisms by which tumor cells evade immune surveillance, focusing on describing the intrinsic and extrinsic mechanisms of resistance to ICIs. We also summarized the impacts of different diets and/or nutrients on the response to ICIs therapy. Combinatory treatments of ICIs therapy with optimized diet regimens own great potential to enhance the efficacy and durable response of ICIs against tumors, which should be routinely considered in clinical settings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/life12030409

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Immune evasion by tumors and effects of dietary factors on immune checkpoint inhibitors (ICIs) therapy. In the priming phase, T cells are activated by antigen-presenting cells (APCs) when T cell receptor (TCR) binds to the antigen displayed in the major histocompatibility complex (MHC) on APCs, e.g., dendritic cells (DCs), in concert with CD28:B7-mediated co-stimulation. In the case of a strong TCR stimulus, CTLA-4 expression is upregulated and competes with CD28 for binding B7 molecules. High levels of CTLA-4:B7 binding limit the survival of T cells and protect tumor cells from T cell attack. In the effector phase, prolonged tumor antigen stimuli cause an upregulation of PD-1 which binds to PD-L1 expressed by tumor cells. PD-1:PD-L1 binding leads to the exhaustion of T cells, which results in immune evasion by tumors. In addition, there are several types of cells, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophage (TAMs), and cancer-associated fibroblast (CAFs), which can inhibit the anti-tumor T-cell response via secreting various molecules. Immune checkpoint inhibitors (ICIs), e.g., anti-CTLA-4 and PD-1/PD-L1 antibodies, can reactivate the immune response of T cells to tumors. Emerging evidence suggests that certain dietary patterns and vitamins can synergistically enhance the efficacy of ICIs therapy by affecting the expression of immune checkpoint proteins.
Figure 1 Immune evasion by tumors and effects of dietary factors on immune checkpoint inhibitors (ICIs) therapy. In the priming phase, T cells are activated by antigen-presenting cells (APCs) when T cell receptor (TCR) binds to the antigen displayed in the major histocompatibility complex (MHC) on APCs, e.g., dendritic cells (DCs), in concert with CD28:B7-mediated co-stimulation. In the case of a strong TCR stimulus, CTLA-4 expression is upregulated and competes with CD28 for binding B7 molecules. High levels of CTLA-4:B7 binding limit the survival of T cells and protect tumor cells from T cell attack. In the effector phase, prolonged tumor antigen stimuli cause an upregulation of PD-1 which binds to PD-L1 expressed by tumor cells. PD-1:PD-L1 binding leads to the exhaustion of T cells, which results in immune evasion by tumors. In addition, there are several types of cells, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophage (TAMs), and cancer-associated fibroblast (CAFs), which can inhibit the anti-tumor T-cell response via secreting various molecules. Immune checkpoint inhibitors (ICIs), e.g., anti-CTLA-4 and PD-1/PD-L1 antibodies, can reactivate the immune response of T cells to tumors. Emerging evidence suggests that certain dietary patterns and vitamins can synergistically enhance the efficacy of ICIs therapy by affecting the expression of immune checkpoint proteins.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 150 references

Research works printed but not linked: 1

  1. Xing, 2021, Advances in research on tumor immunotherapy and its drug development, J. China Pharm. Univ., 52, 10

Cited by

See all 19

Metadata

Authors
Zhang, X., Li, H., Lv, X., Hu, L., Li, W., Zi, M., & He, Y.
Affiliations
  • First Affiliated Hospital of Dalian Medical University (CN)
  • Kunming Institute of Zoology (CN)
  • State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650201, China
  • Third People's Hospital of Yunnan Province (CN)
Corresponding author
He, Yonghan
Venue
Life
Publisher
MDPI AG
Published
2022-03-11
Volume
12
Issue
3
Pages
409
ISSN
2075-1729 (ISSN-L)
OpenAlex
W4221004391
Cited by
18
References
152
Citations by year
2026: 4 · 2025: 3 · 2024: 2 · 2023: 7 · 2022: 2
FWCI
0.43
Type
journal article
Language
en
Open access
Locations
  • Life (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Applied Basic Research Projects of Yunnan Province (202101AS070137, 202101BA070001-110)
  • National Natural Science Foundation of China (82171558)
  • Strategic Priority Research Program of the Chinese Academy of Sciences (XDPB17)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Physiology (medical) › Dietary Effects on Health
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
immune checkpoint inhibitors, diet, cancer immunotherapy, immunotherapy resistance, tumor immune evasion, immune surveillance, nutrients, combination therapy, cancer treatment side effects

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors. https://app.cochat.ai/papers/10.3390/life12030409
The paper
Zhang, X., Li, H., Lv, X., Hu, L., Li, W., Zi, M., & He, Y. (2022). Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors. Life. https://doi.org/10.3390/life12030409

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.